comparemela.com

Latest Breaking News On - Ajay munshi - Page 1 : comparemela.com

Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progres

Enrollment Completed in Selection Phases (Part A) of RAMP 201 and RAMP 202 Evaluating VS-6766 +/- Defactinib for the Treatment of Low-Grade Serous Ovarian Cancer and KRAS G12V Mutant Non-Small Cell Lung CancerCompany Secured up to $150 Million in Non-Dilutive Funding from Oxford Finance LLC; Expected Cash Runway Thr.

Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.